TipRanks
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
Canadian Market
EPRX
Eupraxia Pharmaceuticals
RESEARCH TOOLSreports
Want to see TSE:EPRX full AI Analyst Report?

Eupraxia Pharmaceuticals (EPRX) Stock Forecast & Price Target

80 Followers
See the Price Targets and Ratings of:

EPRX Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Eupraxia
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EPRX Stock 12 Month Forecast

Average Price Target

C$24.16
▲(136.85% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Eupraxia Pharmaceuticals in the last 3 months. The average price target is C$24.16 with a high forecast of C$35.53 and a low forecast of C$15.63. The average price target represents a 136.85% change from the last price of C$10.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"C$7","36":"C$36","14.25":"C$14.25","21.5":"C$21.5","28.75":"C$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.52675525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$35.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.15819357,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$24.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.63177231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$15.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.19,13.062058096153846,14.934116192307693,16.806174288461538,18.678232384615384,20.55029048076923,22.422348576923078,24.294406673076924,26.16646476923077,28.038522865384614,29.910580961538464,31.782639057692307,33.65469715384616,{"y":35.52675525,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.19,12.187553351538462,13.185106703076922,14.182660054615384,15.180213406153847,16.177766757692307,17.175320109230768,18.17287346076923,19.170426812307692,20.167980163846153,21.165533515384617,22.16308686692308,23.160640218461538,{"y":24.15819357,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.19,11.531674793076922,11.873349586153847,12.21502437923077,12.556699172307692,12.898373965384614,13.240048758461539,13.581723551538461,13.923398344615386,14.265073137692308,14.606747930769231,14.948422723846154,15.290097516923078,{"y":15.63177231,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.37,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetC$35.53Average Price TargetC$24.16Lowest Price TargetC$15.63
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on TSE:EPRX
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
C$27
Buy
164.71%
Upside
Reiterated
10/07/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Bloom Burton Analyst forecast on TSE:EPRX
David Martin PhD
Bloom Burton
Bloom Burton
C$19.89
Buy
95.05%
Upside
Reiterated
10/01/26
Bloom Burton Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Wedbush Analyst forecast on TSE:EPRX
Martin Fan
Wedbush
Wedbush
C$24.16
Buy
136.85%
Upside
Reiterated
10/01/26
Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Wedbush
H.C. Wainwright Analyst forecast on TSE:EPRX
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
C$15.63
Buy
53.25%
Upside
Reiterated
10/01/26
Brandon Folkes Reiterates Buy on EP-104GI as New 52-Week Data Reinforce Once-Yearly Dosing Upside; Price Target Unchanged at $11
LifeSci Capital Analyst forecast on TSE:EPRX
Sam Slutsky
LifeSci Capital
LifeSci Capital
C$22.74
Buy
122.91%
Upside
Reiterated
09/30/26
EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
William Blair Analyst forecast on TSE:EPRX
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
09/30/26
EP-104GI’s Strong 52-Week EoE Data and Clean Safety Profile Underpin Buy Rating Ahead of Pivotal Phase IIb Readout
Stifel Nicolaus Analyst forecast on TSE:EPRX
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
C$35.53
Buy
248.30%
Upside
Reiterated
09/24/26
Stifel Nicolaus Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Oppenheimer Analyst forecast on TSE:EPRX
Jay Olson
Oppenheimer
Oppenheimer
C$24.16
Buy
136.85%
Upside
Reiterated
08/12/26
Oppenheimer Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
Craig-Hallum Analyst forecast on TSE:EPRX
Albert Lowe
Craig-Hallum
Craig-Hallum
C$19.89
Buy
95.05%
Upside
Reiterated
05/05/26
Craig-Hallum Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on TSE:EPRX
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
C$27
Buy
164.71%
Upside
Reiterated
10/07/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Bloom Burton Analyst forecast on TSE:EPRX
David Martin PhD
Bloom Burton
Bloom Burton
C$19.89
Buy
95.05%
Upside
Reiterated
10/01/26
Bloom Burton Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Wedbush Analyst forecast on TSE:EPRX
Martin Fan
Wedbush
Wedbush
C$24.16
Buy
136.85%
Upside
Reiterated
10/01/26
Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Wedbush
H.C. Wainwright Analyst forecast on TSE:EPRX
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
C$15.63
Buy
53.25%
Upside
Reiterated
10/01/26
Brandon Folkes Reiterates Buy on EP-104GI as New 52-Week Data Reinforce Once-Yearly Dosing Upside; Price Target Unchanged at $11
LifeSci Capital Analyst forecast on TSE:EPRX
Sam Slutsky
LifeSci Capital
LifeSci Capital
C$22.74
Buy
122.91%
Upside
Reiterated
09/30/26
EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
William Blair Analyst forecast on TSE:EPRX
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
09/30/26
EP-104GI’s Strong 52-Week EoE Data and Clean Safety Profile Underpin Buy Rating Ahead of Pivotal Phase IIb Readout
Stifel Nicolaus Analyst forecast on TSE:EPRX
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
C$35.53
Buy
248.30%
Upside
Reiterated
09/24/26
Stifel Nicolaus Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Oppenheimer Analyst forecast on TSE:EPRX
Jay Olson
Oppenheimer
Oppenheimer
C$24.16
Buy
136.85%
Upside
Reiterated
08/12/26
Oppenheimer Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
Craig-Hallum Analyst forecast on TSE:EPRX
Albert Lowe
Craig-Hallum
Craig-Hallum
C$19.89
Buy
95.05%
Upside
Reiterated
05/05/26
Craig-Hallum Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
ASNDAscendis Pharma
AORTArtivion
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eupraxia Pharmaceuticals

3 Months
Kristen KluskaCantor Fitzgerald
Success Rate
6/9 ratings generated profit
67%
Average Return
+10.04%
Copying Kristen Kluska's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.04% per trade.
1 Year
Albert LoweCraig-Hallum
Success Rate
8/9 ratings generated profit
89%
Average Return
+38.93%
Copying Albert Lowe's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +38.93% per trade.
2 Years
Albert LoweCraig-Hallum
Success Rate
8/9 ratings generated profit
89%
Average Return
+44.00%
Copying Albert Lowe's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +44.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EPRX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
13
15
16
13
Buy
4
3
3
5
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
16
18
21
18
In the current month, EPRX has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EPRX average Analyst price target in the past 3 months is 24.16.
Each month's total comprises the sum of three months' worth of ratings.

EPRX Financial Forecast

EPRX Earnings Forecast

Next quarter’s earnings estimate for EPRX is -C$0.38 with a range of -C$0.46 to -C$0.34. The previous quarter’s EPS was -C$0.32. EPRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EPRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for EPRX is -C$0.38 with a range of -C$0.46 to -C$0.34. The previous quarter’s EPS was -C$0.32. EPRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EPRX has Performed in-line its overall industry.
No data currently available

EPRX Sales Forecast

Next quarter’s sales forecast for EPRX is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were C$0.00. EPRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EPRX has Performed in-line its overall industry.
Next quarter’s sales forecast for EPRX is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were C$0.00. EPRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EPRX has Performed in-line its overall industry.

EPRX Stock Forecast FAQ

What is TSE:EPRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Eupraxia Pharmaceuticals’s 12-month average price target is 24.16.
    What is TSE:EPRX’s upside potential, based on the analysts’ average price target?
    Eupraxia Pharmaceuticals has 136.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TSE:EPRX a Buy, Sell or Hold?
          Eupraxia Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Eupraxia Pharmaceuticals’s price target?
            The average price target for Eupraxia Pharmaceuticals is 24.16. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is C$35.53 ,the lowest forecast is C$15.63. The average price target represents 136.85% Increase from the current price of C$10.2.
              What do analysts say about Eupraxia Pharmaceuticals?
              Eupraxia Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of TSE:EPRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.